Tevogen Secures $3M PIPE at $8 Per Warrant, 14% Premium
Tevogen raised $3 million through a private placement issuing 375,000 prefunded warrants at $8 each, representing a 14% premium to the May 11 closing price. Proceeds will fund operations, strategic growth initiatives and general corporate purposes, with closing expected on May 13, 2026.
1. Financing Details
Tevogen entered a $3 million PIPE financing with The Patel Family, LLP, issuing 375,000 prefunded warrants exercisable at $8 per warrant. This pricing represents a 14% premium to the May 11 closing price, and the transaction is expected to close on or about May 13, 2026.
2. Use of Proceeds
Proceeds are earmarked to support ongoing operations, advance strategic growth initiatives and cover general corporate purposes. This financing augments an existing at-the-market offering and loan agreement, providing enhanced capital flexibility.
3. Investor Confidence
The Patel Family's continued participation underscores their conviction in Tevogen’s leadership, AI-driven T cell therapy platform and long-term vision. Their commitment to remain long-term holders reflects shared belief in the company’s mission to develop scalable healthcare solutions.
4. Strategic Outlook
The new capital will extend Tevogen’s cash runway and back revenue-driving efforts across its virology, oncology and neurology programs. Management plans to leverage the ExacTcell platform and AI-based drug development tools to accelerate pipeline progress toward upcoming clinical inflection points.